American Pharmaceutical Partners receives two FDA approvals for octreotide acetate injection

By Angela McDaniels

Seattle, Feb. 13 - American Pharmaceutical Partners Inc. said the Food and Drug Administration has approved the company's Abbreviated New Drug Applications for single-dose and multiple-dose vials of octreotide acetate injection.

The product is the generic equivalent of Novartis Pharmaceutical Corp.'s Sandostatin injection, sales of which exceeded $145 million in 2005, according to a company news release.

American Pharmaceutical Partners said it will begin marketing octreotide acetate shortly.

Octreotide acetate injection is indicated for the treatment of agromegal, the excessive secretion of growth hormone. It is also used to reduce flushing and watery diarrhea caused by metastatic cancerous tumors or vasoactive intestinal peptide tumors.

American Pharmaceutical Partners is a specialty drug company based in Schaumburg, Ill., that develops, manufactures and markets injectable pharmaceutical products with a focus on the oncology, anti-infective and critical care markets.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.